Recursion Adds New Chemical Entity Targeting Fibrotic Diseases To Late Discovery Pipeline; Signed An Agreement With Bayer AG To In-License A New Chemical Entity That Emerged From The Companies' Fibrosis Research Collaboration
Portfolio Pulse from Benzinga Newsdesk
Recursion (NASDAQ:RXRX) has signed an agreement with Bayer AG to in-license a new chemical entity from their fibrosis research collaboration. This compound has shown potential to reverse fibrotic processes and is now part of Recursion's late discovery pipeline. The company's technology enabled the identification of small molecules that can potentially treat fibrotic diseases, which are a major health concern with high unmet needs.
January 04, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Recursion has expanded its late discovery pipeline with a new chemical entity targeting fibrotic diseases, licensed from Bayer AG, showcasing the potential of its drug discovery platform.
The licensing of a new chemical entity from Bayer AG is a positive development for Recursion, indicating progress in its collaboration and potential for future drug development. This news may increase investor confidence in Recursion's drug discovery capabilities and its pipeline's potential, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90